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About this Paper
Legislation introduced by two members of the District of Columbia
Council on January 9, 2007 would require all girls to be vaccinated against
the human papillomavirus (HPV), the primary cause of cervical cancer, by
the time they enter the sixth grade, unless a parent or guardian speciﬁcally
“opts out” of the mandate. A similar bill was introduced last week in
Virginia, and Maryland and West Virginia are poised to consider legislation.
To place the proposals in a broader context, this paper reviews some of the
scientiﬁc, legal, ethical and ﬁnancial issues surrounding the HPV vaccine
and compulsory vaccinations. The paper is being issued through the Jacobs
Institute of Women’s Health, which is afﬁliated with the School of Public
Health and Health Services.

For more information about the HPV vaccine:
Alexandra Stewart, JD
Assistant Research Professor
Department of Health Policy
School of Public Health and Health Services
The George Washington University
2021 K Street, N.W., Suite 800
Washington, DC 20006
202-530-2331
E-mail: stewarta@gwu.edu

About the Rapid Public Health Policy Response Project
The Rapid Public Health Policy Response Project of the School of
Public Health and Health Services at The George Washington University
provides data and other background information on breaking public
health stories. The goal is to educate the public, policymakers, legislators,
health care providers, the media and others in order to promote informed
decisionmaking. The Public Health and Policy Group of Pﬁzer, Inc.
provides support for this project.
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HPV Vaccination: Should it be Recommended or Required?
In June 2006, the federal Food and Drug Administration (FDA) approved the ﬁrst vaccine
to protect females, ages 9-26, against four strains of the human papillomavirus (HPV). Two
of these strains (strains 16 and 18) cause about 70% of all cases of cervical cancer; the
other two (strains 6 and 11) cause 90% of all genital warts. The Advisory Committee on
Immunization Practices (ACIP), a part of the Centers for Disease Control and Prevention,
now recommends immunizing all girls and young women.
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“Our challenge now is to determine how best to bring this tremendous medical
breakthrough to the greatest number of people,” says Alexandra Stewart, JD, Assistant
Research Professor in the Department of Health Policy at GW’s School of Public Health
and Health Services. “In the past, policymakers have effectively used school mandates to
achieve almost universal vaccination. That strategy is again being seriously considered.”

The Problem
HPV infection is the most common sexually-transmitted disease in the United States,
present in more than three-quarters of all women by age 50. There are more than 100
strains of the virus, about 30 of which cause some form of genital infection. While often
asymptomatic, HPV was responsible for almost 500,000 new cases of cervical cancer and
some 250,000 deaths around the world in 2005, mostly in developing countries, according
to the World Health Organization.
Cervical cancer is less common in the United States, where Pap smears, which can
detect pre-cancerous cell changes and early-stage disease, are routine. Nonetheless, about
10,000 new cases, and 3,700 deaths occur annually in this country, disproportionately
affecting African-American and Hispanic women. Nationwide, 8.8 women per 100,000 are
diagnosed with cervical cancer; in the District of Columbia, the incidence rate is 13.5 per
100,000. Death rates in the District are more than double national averages.1

The Medical Advance
The HPV vaccine—called Gardasil and manufactured by Merck—is administered in
three doses (dose one, followed in two months by dose two, and four months later by dose
three)—and is safe and effective. The studies on which FDA approval was based identiﬁed
only minor pain at the injection site as a common side effect. While it does nothing to treat
existing infection, the vaccine confers almost 100% protection against new infections of
the target HPV strains. Studies to date have shown immunization to be effective for ﬁve
years; a booster shot may eventually be required to sustain protection. Because the vaccine
does not target all cervical cancer-causing strains of HPV, Pap smears will continue to be
recommended to sexually active females.2
The Advisory Committee on Immunization Practices now recommends that girls
be routinely vaccinated against HPV at age 11 or 12 and that a catch-up vaccine be
administered to females, ages 13 to 26, if they have not already been vaccinated. ACIP also
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notes that the vaccine can be given to girls as young as 9. While its recommendations are
not binding, they typically become the standard of care.3

Protecting the Target Audience
Because HPV infection is a sexually transmitted disease, the use of the vaccine, and
especially proposals to make its use mandatory, take on added complexity and controversy.
Might parents hesitate to approve vaccinations for their children for fear of suggesting that
it is acceptable to be sexually active? Might the stigma of sexually transmitted diseases lead
women to avoid the vaccine? Will clinicians recommend it?
The research shows that young women are very interested in getting the HPV vaccine,
and are particularly receptive when it has been recommended by their doctors.4 Likewise,
parents educated about its value are generally willing to have their children vaccinated. And
clinicians are inclined to offer the HPV vaccine in their practices, especially where it has the
support of their professional associations. Both the American College of Obstetricians and
Gynecologists and the American Academy of Pediatrics endorse the use of the vaccine by
their members.5
Experts emphasize the importance of creating immunization opportunities, especially
given the challenge of reaching adolescents and the need to administer three doses within a
short time period. Standards of preventive care are not well-established for this population
and they tend to receive few well-child exams. Indeed, people in their teens and early 20s
make fewer visits to physicians’ ofﬁces than at any other time in their lives and currently fail
to receive at least one of the other vaccines recommended for them.6,7 Given the widespread
prevalence of HPV, the goal of the vaccine is to confer immunity before a girl has initiated
any sexual activity. With 26% of females having vaginal intercourse by age 15, and most
becoming sexually active at some point in their teenage years, that means inoculating them
young.8

Should the Vaccine be Mandatory?
The HPV Vaccination Reporting Act of 2007, introduced to the D.C. Council on January
9th, would require certiﬁcation that a girl has received the HPV vaccine prior to her
enrollment in sixth grade.9 Parents would be permitted to opt-out of the requirement on
terms that have not yet been speciﬁed. California, Kentucky, Maryland, South Carolina,
Virginia and West Virginia are also considering mandatory HPV vaccination. A similar
proposal was defeated in Michigan last month.
Studies show that state laws requiring immunization as a condition of enrollment in
school increase the use of vaccines, reduce disease, lessen racial disparities in coverage
and increase available funding.10 “Requiring HPV vaccination by law will almost certainly
achieve more widespread protection against the disease than will policies that rely
exclusively on persuasion and education,” writes one commentator.11 That does not mean
there is a consensus that HPV vaccination should be mandatory.
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State Vaccine Mandates: Vaccination requirements are established on a state-by-state
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basis; there are no federal mandates. The legal precedent for mandatory vaccinations is
the 1907 decision in Jacobsen v Massachusetts, when the U.S. Supreme Court upheld a
Massachusetts law requiring smallpox vaccinations for adults, declaring that “the police
power of a State must be held to embrace, at least, such reasonable regulations... as will
protect the public health and the public safety.”12
The diphtheria/pertussis/tetanus, measles/mumps/rubella and polio vaccines are almost
universally required for children entering school; laws covering haemophilius inﬂuenzae
Type B, hepatitis B, and varicella (chicken pox) vaccines vary.13 Exemptions on medical
grounds are permitted everywhere. Most states also allow religious exemptions, and 20
provide “personal-belief” exemptions, which vary in their ﬂexibility. States that offer personal
belief exemptions, and those that make any exemptions easy to get, have higher rates of
unvaccinated children. They also have higher disease rates – for example, the incidence of
pertussis (whooping cough) is twice as high in states that allow personal belief exemptions,
compared to those that offer only religious exemptions.14
Despite the social movement of some force and visibility that has arisen in recent years
to question the safety and value of vaccines, more than 95 percent of school-age American
children ultimately receive the mandated immunizations.15 Contagious diseases have
dropped dramatically as a direct result. A single example: an average of 500,000 children
contracted measles in the years shortly before the vaccine was introduced; in 2000, there
were 81 cases of measles.16
The HPV Debate: The traditional basis for school immunization mandates is to protect
school-age children and the community at large from communicable disease. Public
health experts argue for requiring vaccinations because they provide protection not only
to vaccinated individuals, but also to the community as a whole. “Herd immunity” occurs
when enough people are protected against the disease to slow or halt person-to-person
transmission, even to those who are not vaccinated because they slip through the cracks of
the medical system or are exempt for medical, religious or personal reasons.
An additional argument for an HPV vaccine mandate tied to school enrollment is
the absence of consistent venues for serving adolescents. In general, adolescents and
young adults have poorer access to care than any other population in the United States.
The National Adolescent Health Information Center says that “a signiﬁcant minority [of
adolescents]—including the uninsured, the poor, some racial/ethnic groups and adolescents
with special risk factors—report having foregone needed care and having unmet health
needs.”17 If the HPV vaccine remains voluntary, adolescents in medically underserved
communities are less likely to receive it, and another health disparity may well emerge
between those who have ready access to medical care and those who do not.
But public health concerns must be weighed against bioethical considerations, which
generally place paramount value on respect for individual liberties, autonomy and the need
to obtain informed consent for medical treatment.
GW SPHHS Rapid Public Health Policy Response Project

| January 2007

3

GW

HPV Vaccination: Should it be Recommended or Required?
Where a disease is transmitted through casual contact or airborne droplets, and a thirdparty—such as a child who is medically ineligible for the measles vaccine—is placed at
increased risk because someone else refuses vaccination, the public health advantage of
mandatory vaccines has generally held sway. But because HPV infection is transmitted only
through sexual contact, it provokes more scrutiny from bioethicists and others who want to
limit the intrusion of government into the lives of its people. Towards that goal, some have
argued that compulsory vaccination is “unacceptably paternalistic.”18
Other objections to an HPV mandate focus on parental rights and concerns about
condoning sexual activity in adolescence.19 There are also deep sensitivities in communities
of color about stereotyping their sexual behavior. In a Washington Post opinion piece,
Courtland Milloy writes that the DC proposal to vaccinate girls in school is built on this
notion: “After all, your daughter is 11 and probably black, so the assumption is she’ll be
having unprotected sex in no time – but don’t take offense.”20 Milloy also raises the specter
of the Tuskegee experiments, in which black men were deliberately left untreated for
syphilis, as a reminder that when it comes to medical treatment, government intent has not
always been benign.

Paying the Costs
At a price of $360 for the required three doses, the HPV vaccine is one of the most expensive
on the market. Whether or not vaccination becomes mandatory around the country, cost
issues will need to be addressed.
Private insurance companies are likely to pay for it, because they typically base
reimbursement decisions on the guidelines of the Advisory Committee on Immunization.
All Medicaid-eligible children under 21 are covered for all ACIP-approved vaccines, as are
American Indian and Alaska Native teens under 18, and adolescents under 18 enrolled in
the State Children’s Health Insurance Program. Federally funded community health centers,
which charge for services on a sliding scale, may be another affordable source of coverage.
Many states have additional mechanisms to vaccinate children, either through public clinics
or by providing free supplies to private providers.21
Vaccine coverage for adults is more problematic. Under Medicaid, vaccines are an
optional beneﬁt determined at the state level. Some states choose to provide some or all
adults with free or low-cost vaccines at public clinics and affordable coverage is sometimes
available at community health centers. Additionally, Merck has said it will provide limited
free HPV vaccine through its patient assistance program to women who meet eligibility
requirements based on income.22 Nonetheless, these piecemeal approaches will miss many
women, leaving them either to pay for the vaccines themselves, or go without potentially
lifesaving protection.

In Conclusion
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The approval of the HPV vaccine represents a signiﬁcant breakthrough for women’s
health. Now, the challenge is to ﬁnd the best way to immunize as many girls and women as
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possible before they become infected with the virus that causes cervical cancer. That will
require careful debate about the relative risks and beneﬁts of policies that rely on voluntary
compliance with public health recommendations, compared to policies that mandate
vaccination as a condition of school enrollment.
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Notes on Sources
Ü

1

The incidence data on cervical cancer are drawn from multiple sources,
including the Kaiser Family Foundation’s background brief, “HPV, Cervical
Cancer and the New Vaccine,” which provides electronic links to additional
data sources; the World Health Organization’s Comprehensive Cervical
Cancer Control (2006); the National Cancer Institute SEER Cancer
Statistics; and the DC Department of Health’s Division of Cancer Control,
where a chart comparing DC and U.S. cervical cancer incidence and
mortality rates among black and white women is available.

Ü

2

Information about approval of the HPV vaccine, the trials on which it was
based, and safety and efﬁcacy ﬁndings are available at the FDA’s Center for
Biological Evaluation and Research (CBER).

Ü

3

ACIP’s recommended immunization schedule for children from birth to 18,
including HPV, is published in Morbidity and Mortality Weekly Report, January
5, 2007.

Ü

4

Two articles by Gregory D. Zimet review research on the attitudes of young
women, parents and clinicians towards the HPV vaccine: “Understanding and
Overcoming Barriers to Human Papillomavirus Vaccine Acceptance” (Current
Opinion in Obstetrics and Gynecology, 2006) and “Improving Adolescent
Health: Focus on HPV Vaccine Acceptance” (Journal of Adolescent Health,
2005).

Ü

5

The American College of Obstetricians and Gynecologists released its
HPV vaccine recommendations for its members in an August 8, 2006 press
release. The American Academy of Pediatrics included the HPV vaccine in its
recommended 2007 immunization schedule, issued January 2, 2007.

Ü

6

See Sharon Humiston and Susan Rosenthal, “Challenges to Vaccinating
Adolescents: Vaccine Implementation Issues,” (Pediatric Infectious Disease
Journal, June 2005).

Ü

7

“Adolescent Vaccination: Bridging from a Strong Childhood to a Healthy
Adulthood,” published in 2005 by the National Foundation for Infectious
Diseases, describes current challenges to reaching adolescents with vaccines,
and strategies for overcoming them.

Ü

8

Data on sexual activities were collected in the 2002 National Survey of
Family Growth conducted by the CDC’s National Center for Health
Statistics and published in “Sexual Behavior and Selected Health Measures:
Men and Women 15–44 Years of Age, United States, 2002,” Ádvance Data
from Vital and Health Statistics, No. 362, September 15, 2005.
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Ü

9

Ü

10

Walter Orenstein and Alan Hinman describe the “safety net” provided by
school-based immunization in “The Immunization System in the United
States—the Role of School Immunization Laws,” (Vaccine, 1999).

Ü

11

James Colgrove explores the debate in “The Ethics and Politics of
Compulsory HPV Vaccination” (New England Journal of Medicine,
December 7, 2006).

Ü

12

The Supreme Court established the right of states to mandate vaccinations
in Jacobsen v. Massachusetts (197 U.S. 11, 25 S.Ct 358, 1905). Subsequent
key decisions include Zucht v. King (260 US 174, 43 S.Ct. 24, 1922), which
upheld the constitutionality of city ordinances excluding unvaccinated
children from school and Maricopa County Health Department v. Harmon
(156 Ariz. 161, 750 P.2nd 1364, 1987), which determined that an
individual’s right to education did not trump the state’s right to require
measles vaccination, even in the absence of an outbreak at a particular
school.

Ü

13

James G. Hodge, Jr. reviews existing state laws concerning vaccinations in
“School Vaccination Requirements: Legal and Social Perspectives” (National
Conference of State Legislatures State Legislative Report, August 2002).

Ü

14

Saad Omer and colleagues review state exemption policies and their impact
on vaccination rates in “Nonmedical Exemptions to School Immunization
Requirements” (Journal of the American Medical Association, October 11,
2006). An international perspective is provided by Daniela Almon and
colleagues in “Compulsory Vaccination and Conscientious or Philosophical
Exemptions: Past, Present and Future” (Lancet, February 4, 2006). Stateby-state descriptions of criteria for vaccine exemptions at the Institute for
Vaccine Safety.

Ü

15

In addition to noting the 95 percent vaccination rate, James G. Hodge, Jr.
describes historic and contemporary objections to mandatory vaccination in
“School Vaccination Requirements: Legal and Social Perspectives” (National
Conference of State Legislatures State Legislative Report, August 2002).

Ü

16

A table comparing the average annual incidence, prior to the introduction of
a vaccine, of 10 vaccine-preventable diseases with 2000 ﬁgures is available
in Kevin M. Malone and Alan R. Hinman, “Vaccine Mandates: The Public
Health Imperative and Individual Rights,” a chapter in Law in Public Health
Practice (Oxford University Press, 2003).

Bill B17-30 was introduced by Council members David A. Catania and Mary
M. Cheh.
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Ü

17

Background about adolescent health care is available in an Adolescent and
School Health Fact Sheet, August 2005, prepared by the Association of
State and Territorial Health Ofﬁcials; at the National Adolescent Health
Information Center at the University of California, San Francisco; and in the
NAHIC publication America’s Adolescents: Are They Healthy? ( 2003), which
is the source of the quote.

Ü

18

James Colgrove, “The Ethics and Politics of Compulsory HPV Vaccination”
(New England Journal of Medicine, December 7, 2006).

Ü

19

See, for example, the statement of the Family Research Council to the
Advisory Committee on Immunization Practices, August 24, 2006.

Ü

20

Courtland Milloy, “District’s HPV Proposal Tinged With Ugly Assumptions”
(Washington Post, January 10, 2007).

Ü

21

For a detailed discussions of vaccine ﬁnancing mechanisms, see Gary L.
Freed, Sarah J. Clark and Anne E. Cowan, “State-Level Perspectives on
Immunization Policies, Practices, and Program Financing in the 1990s”
(American Journal of Preventive Medicine, 2000).

Ü

22

Information about Merck’s patient assistance program is available online or
by calling (800) 293-3881.
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